REFILE-BUZZ-U.S. Stocks on the Move-Intellipharmaceuticals, Quiksilver
(Corrects company name to Quiksilver from Quicksilver in headline and text. The error also appeared in earlier versions) (For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)
U.S. stocks were little changed on Friday and the benchmark S&P 500 was on pace for its first weekly drop in five, following a weak payrolls report that reassured investors the Federal Reserve wouldn't speed up plans to hike interest rates. The Dow Jones industrial average was down 0.20 percent at 17,035.61, the S&P 500 was down 0.21 percent at 1,993.42 and the Nasdaq Composite was down 0.01 percent at 4,561.89.
** PRANA BIOTECHNOLOGY LTD, $2.59, +21.03 pct
The drug developer received orphan status from the U.S. FDA for its Huntington's disease drug, PBT2, entitling the Australian company to seven years of exclusivity.
The lead drug aims to treat Huntington's disease, a type of brain disorder, for which there's no current cure. Up to Thursday's close, the stock was down about 78 percent since March 31, when the company said the drug failed a mid-stage study testing for treatment of Alzheimer's disease.
** VERTEX PHARMACEUTICALS INC, $94.84, +3.59 pct Continued...